CoChat
Sign Up
Cited by 235Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

Open access
Santini, Daniele, Loupakis, Fotios, Vincenzi, Bruno, Floriani, Irene, Stasi, Irene, Canestrari, Emanuele, Rulli, Eliana, Maltese, Paolo Enrico, Andreoni, Francesca, Masi, Gianluca, Graziano, Francesco, Baldi, Giacomo Giulio, Salvatore, Lisa, Russo, Antonio, Perrone, Giuseppe, Tommasino, Maria Rosa, Magnani, Mauro, Falcone, Alfredo, Tonini, Giuseppe, Ruzzo, Annamaria·2008·The Oncologist
DOI 10.1634/theoncologist.2008-0181
Open this paper in CoChat — free accountOpen PDF

Abstract

Purpose.: Several studies have suggested that KRAS somatic mutations may predict resistance to cetuximab- and panitumumab-based treatments in metastatic colorectal cancer (CRC) patients. Nevertheless, most experiences were conducted on samples from primaries. The aim of this study was to evaluate the grade of concordance in terms of KRAS status between primaries and related metastases. Patients and Methods.: We analyzed KRAS codon 12 and 13 mutations from formalin-fixed sections of 107 CRC primaries and related metastases. Eight pairs were excluded from the analysis because of the low amount of tumor tissue in the available samples. The main characteristics were: 50 men, 49 women; median age at diagnosis, 71 years (range, 41–84). The metastatic sites analyzed were the liver in 80 patients (80.8%), lung in seven patients (7.1%), and other sites in 12 patients (12.1%). Results.: A KRAS mutation was found in 38 (38.4%) primary tumors and in 36 (36.4%) related metastases. The rate of concordance was 96.0% (95% confidence interval, 90.0%–98.9%). Discordance was observed in only four (4%) patients. Conclusions.: Our results indicate that the detection of KRAS mutations in either primary or metastatic tumors from patients with CRC is concordant and this assessment could be used to predict response to targeted therapies such as cetuximab and panitumumab. Learning Objectives: After completing this course, the reader should be able to: Describe the importance of KRAS mutations in CRC patients.Explain the relevance to cancer treatment of concordance of KRAS status between primary tumors and metastases in CRC patients.Discuss the impact of KRAS mutations as a predictive/prognostic factor in CRC patients. CME This article is available for continuing medical education credit at http://CME.TheOncologist.com

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2008-0181

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Molinari, 2008, Analysis of epidermal growth factor receptor (EGFR) gene status and protein expression, and K-ras gene mutations in metastatic colorectal cancer patients: Comparison between primary tumor and related metastatic sites, Ann Oncol, 19, i10

Cited by

Sorted by citations

Items 101–200 of 235

Related

See all

Metadata

Authors
Santini, D., Loupakis, F., Vincenzi, B., Floriani, I., Stasi, I., Canestrari, E., Rulli, E., Maltese, P. E., Andreoni, F., Masi, G., Graziano, F., Baldi, G. G., Salvatore, L., Russo, A., Perrone, G., Tommasino, M. R., Magnani, M., Falcone, A., Tonini, G., & Ruzzo, A.
Affiliations
  • Università Campus Bio-Medico (IT)
  • University of Pisa (IT)
  • Mario Negri Institute for Pharmacological Research (IT)
  • Ospedale di Livorno (IT)
  • University of Urbino (IT)
  • San Salvatore Hospital (IT)
  • University of Palermo (IT)
Corresponding author
Santini, Daniele
ORCID
Venue
The Oncologist
Publisher
Oxford University Press (OUP)
Published
2008-12-01
Volume
13
Issue
12
Pages
1270-1275
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
DOI
10.1634/theoncologist.2008-0181
OpenAlex
W2121765653
Cited by
234
References
24
Citations by year
2026: 1 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 4 · 2017: 9 · 2016: 20 · 2015: 23 · 2014: 16 · 2013: 23 · 2012: 32
FWCI
11.64
Type
journal article
Language
en
Open access
Licence
Locations
  • The Oncologist (publishedVersion)
  • PubMed (publishedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
KRAS mutation, metastatic colorectal cancer, cetuximab resistance, predictive biomarkers, liver metastasis, lung metastasis, targeted therapy response
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Proto-Oncogene Proteins, Genes, ras, Retrospective Studies, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ras Proteins, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review